Drugs / pCAR-19B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04888442 | Oct 2020 → Jan 2022 | acute lymphoblastic leukemia | Chongqing Precision Biotech Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pCAR-19B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04888442 ↗ |
| Modality | Cell therapy | “Anti-CD19 CAR-T Therapy (pCAR-19B)” NCT04888442 ↗ |
| Route | Intravenous | “pCAR-19B will be infused to the subject by intravenous infusion.” NCT04888442 ↗ |
| Target | CD19 | “Anti-CD19 CAR-T Therapy” NCT04888442 ↗ |